D-0166-2027 Class II Ongoing
FDA drug recall D-0166-2027 was initiated by Hikma Pharmaceuticals USA INC. on Oct 20, 2026 and is designated Class II. Reason for recall: CGMP Deviations: N-nitroso-ciprofloxacin results above the FDA recommended interim control limit. The recall status is ongoing. Affected quantity: 20,335 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 11, 2026
- Initiation Date
- Oct 20, 2026
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 20,335 bottles
Product description
Ciprofloxacin Tablets, USP, 750 mg, 50-count bottle, Rx Only, Manufactured by: Hikma Pharmaceuticals, P.O. Box 182400, Amman, 11118-Jordan, Distributed by: Hikma Pharmaceuticals USA Inc. Berkely Heights, NJ 07922, NDC 0143-9929-50
Reason for recall
CGMP Deviations: N-nitroso-ciprofloxacin results above the FDA recommended interim control limit.
Distribution pattern
US Nationwide
Code information
Lot# CA083A Exp. 12/31/2026 Lot# CA084A Exp. 12/31/2026 Lot# CA085A Exp. 12/31/2026
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0166-2027
- openFDA file date
- Nov 19, 2026
- Loaded by RegDataLab
- Nov 20, 2026
Need the full FDA record for Hikma Pharmaceuticals USA INC.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.